Rapid development and troubleshooting of robust microfluidic antibody-based therapeutic quantification for pharmacokinetic (PK) and toxicokinetic (TK) study support.
Discovery and development of monoclonal antibody (mAb) based therapeutics requires robust immunoassays for quantification to support pharmacokinetic and toxicokinetic studies. A flexible assay design is critical to support multiple species and programs with large numbers of samples, conditions and limited reagents. In this presentation, data from rapid development of microfluidic, flow-through Gyrolab® immunoassays leveraging 1-hour assay times and unique software Viewer features for assay troubleshooting is presented. Advantages of these assays in COVID-19 related laboratory schedules and restrictions is also discussed.
This webinar was presented at Antibodies, Next-Generation Proteins & Bioconjugates Digital Week hosted by Informa Connect on March 1, 2021.